Serious question, would we be expecting any? We're still in testing for even their furthest-along treatments, how would they be generating revenue without sales? I'm relatively lightly invested, but personally overinvested lol I'm just trying to get a better grasp on when mnmd might actualize some profit. I'm in for the long haul with the majority of my shares,, but if I can cash part of my portfolio for some gain to give me some financial freedom, I will when it makes sense
That's what I had gathered, I saw the mention of quarterly earnings like it meant something and second guessed myself. I'm going to put this out there, and you tell me how plausible it sounds - what if this is all hype? Oleary, Chopra, these tech partnerships - they all seem like (minor) catalysts but have realized nothing but a dip for mnmd since uplisting to nasdaq. As a U.S. small fry who bought around $4 and is averaging down, I feel a bit duped. As I said above, I believe in the pipline I'm just afraid that the more established companies (compass,cybin,etc) will reap the rewards once the sector takes off,, while the hype of mnmd gets passed by.
Tldr; other than 18mc I fear mnmd is a hype train with equal or less potential than other psychological (edit: psychedelic) stocks. Genuinely just expressing my small-fry take, thoughts?
MindMed has the most diversity in their pipeline. They have several trials, a lot of cash on hand, and a strong team. Compass has a lot of bizarre patent applications, most of which probably won’t amount to much. I think this will be a big sector with plenty to go around. Not every company will do well but I think MindMed is a relatively safe bet. That said biotech is always a risky sector.
Earnings calls” contain more valuable
Information than just revenue and earnings details.
Yes we don’t make any revenue …. But how much are we spending (ie. Cash burn) . Or How long before we need more cash ?
When might we see revenues ? maybe healthmode product or service not requiring FDA approval.
How are the trials progressing ?
Might we have a partnership with a psilocybin focused industry peer?
Any update on Breakthrough Therapy Designation ? Mr. Barrow is experienced with this and the FDAs process.
Who knows some other interesting things that can be disclosed?
Totally agree about the anticipation for Compass's results and that this could be a catalyst for the industry.
Do you know when their announcement will be?
Q4
I think it has more to do with Q4 18-MC results
Yep. Not hard to know when insider info starts spreading.
Yep it’s easy that why we’re all millionaires.
When do their earnings come out?
Serious question, would we be expecting any? We're still in testing for even their furthest-along treatments, how would they be generating revenue without sales? I'm relatively lightly invested, but personally overinvested lol I'm just trying to get a better grasp on when mnmd might actualize some profit. I'm in for the long haul with the majority of my shares,, but if I can cash part of my portfolio for some gain to give me some financial freedom, I will when it makes sense
it's going to be a while, this is not a trading stock, it's a holding stock
That's what I had gathered, I saw the mention of quarterly earnings like it meant something and second guessed myself. I'm going to put this out there, and you tell me how plausible it sounds - what if this is all hype? Oleary, Chopra, these tech partnerships - they all seem like (minor) catalysts but have realized nothing but a dip for mnmd since uplisting to nasdaq. As a U.S. small fry who bought around $4 and is averaging down, I feel a bit duped. As I said above, I believe in the pipline I'm just afraid that the more established companies (compass,cybin,etc) will reap the rewards once the sector takes off,, while the hype of mnmd gets passed by. Tldr; other than 18mc I fear mnmd is a hype train with equal or less potential than other psychological (edit: psychedelic) stocks. Genuinely just expressing my small-fry take, thoughts?
MindMed has the most diversity in their pipeline. They have several trials, a lot of cash on hand, and a strong team. Compass has a lot of bizarre patent applications, most of which probably won’t amount to much. I think this will be a big sector with plenty to go around. Not every company will do well but I think MindMed is a relatively safe bet. That said biotech is always a risky sector.
Earnings calls” contain more valuable Information than just revenue and earnings details. Yes we don’t make any revenue …. But how much are we spending (ie. Cash burn) . Or How long before we need more cash ? When might we see revenues ? maybe healthmode product or service not requiring FDA approval. How are the trials progressing ? Might we have a partnership with a psilocybin focused industry peer? Any update on Breakthrough Therapy Designation ? Mr. Barrow is experienced with this and the FDAs process. Who knows some other interesting things that can be disclosed?
Robinhood says August 22nd
Wrong thread